Antibody Journal
Articles about Antibody Journal (0)
-
HEK293 vs. CHO for HTP Expression: Impact on Glycosylation and Folding
Choosing an expression host defines an antibody’s biological signature. While HEK293 is often used for convenience, it introduces significant risks in glycosylation and folding. By aligning HTP screening with CHO-native standards from the start, discovery teams eliminate host-switch leads are truly ready for clinical success.
-
Transient vs. Stable Expression in High-Throughput Antibody Screening: When to Switch
The choice between transient and stable expression defines the pace and precision of an antibody program. While transient systems provide the agility for high-throughput screening, stable cell lines offer the consistency required for clinical manufacturing. Understanding the technical triggers for this switch is essential for optimizing timelines and ensuring manufacturing success.
-
Physical Validation at Scale: How HTP Supports AI-Designed Antibody Discovery
AI accelerates antibody discovery, but physical validation remains essential to bridge the gap between digital design and biological reality. High-Throughput (HTP) platforms enable a ‘lab-in-the-loop’ approach, providing the manufacturing-relevant CHO data needed to refine predictive models and ensure that AI-generated candidates are truly developable from the earliest stage.
-
Fail Fast, Succeed Faster: The Role of Early Developability Assessment
Shifting developability assessment to the early discovery phase represents a strategic opportunity to eliminate high risk candidates before significant investment. By utilizing CHO based expression from the very first screening you ensure that early data is truly predictive of manufacturing success. This proactive approach de risks the journey from the bench to preclinical validation by identifying structural liabilities before they become costly failures.
-
Polyclonal Antibody Production: A Comprehensive Guide
This article will provide a comprehensive guide to polyclonal antibody production (pAb production), outlining the steps involved in the process, discussing the advantages and disadvantages of using polyclonal antibodies, and exploring the alternatives to polyclonal antibody production, including recombinant antibody production.
-
Bispecific Antibody Formats – exploring the diverse types & formats in therapeutic development
In this article, we’ll explore the different types and formats of bsAbs, their unique features, and therapeutic applications. Additionally, we’ll highlight evitria’s role in advancing bsAb development.
-
FDA approved bispecific antibodies
Especially in the past decade, the FDA has approved several bispecific antibody (bsAb) products, revolutionizing the treatment of myriad medical conditions. In this article, we will take a look at the bsAbs currently approved by the FDA.
-
Bispecific Antibodies: A Comprehensive Overview
BsAbs are a comparatively new and extremely promising class of antibodies. In this article, we provide an overview of bispecific antibodies, including their mechanism of action and expressions.
-
Antibody-Dependent Cellular Cytotoxicity (ADCC) – Definition, Mechanism & Application
Antibody-dependent cellular cytotoxicity is a key process of the immune system’s arsenal to ward off cancerous cells and infections. We show you important definitions and the ADCC mechanism and key facts on ADCC antibodies in this post.
-
Speed vs. Quality in Early Drug Development: Striking the Right Balance for Antibody Therapeutics
In drug development, speed without reproducibility risks costly setbacks. This article shows how high-quality antibody materials, early testing, and smart design enable faster, more reliable programs without compromising rigor.
